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Type 2 diabetes (T2D) evolves when insulin secretion
fails. Insulin release from the pancreatic b cell is
controlled by mitochondrial metabolism, which
translates fluctuations in blood glucose into meta-
bolic coupling signals. We identified a common
variant (rs950994) in the human transcription factor
B1 mitochondrial (TFB1M) gene associated with
reduced insulin secretion, elevated postprandial
glucose levels, and future risk of T2D. Because islet
TFB1M mRNA levels were lower in carriers of the
risk allele and correlated with insulin secretion, we
examined mice heterozygous for Tfb1m deficiency.
These mice displayed lower expression of TFB1M
in islets and impaired mitochondrial function and
released less insulin in response to glucose in vivo
and in vitro. Reducing TFB1M mRNA and protein
in clonal b cells by RNA interference impaired
complexes of the mitochondrial oxidative phosphor-
ylation system. Consequently, nutrient-stimulated
ATP generation was reduced, leading to perturbed
insulin secretion. We conclude that a deficiency in
TFB1M and impaired mitochondrial function contri-
bute to the pathogenesis of T2D.
INTRODUCTION
Type 2 diabetes (T2D) is a multifactorial and polygenic disorder,
characterized by impaired insulin secretion from pancreatic
b cells and insulin resistance in peripheral tissues. Insulin secre-
tion is controlled by fuel metabolism in pancreatic b cells. When
plasma glucose levels rise, glucose is transported into the b cells80 Cell Metabolism 13, 80–91, January 5, 2011 ª2011 Elsevier Inc.and metabolized, generating metabolic coupling signals that
trigger and amplify exocytosis (Henquin, 2009). In target tissues
of insulin, the hormone controls glucose metabolism, including
regulation of mitochondrial metabolism. In view of these funda-
mental principles, it is of no surprise that mitochondrial dysfunc-
tion has been implicated both in impaired insulin secretion and
action. These pathogenic processes both precede manifest
T2D. In fact, patients with mitochondrial dysfunction caused by
mutations in mitochondrial DNA (mtDNA) often develop impaired
insulin secretion (Goto et al., 1990; Reardon et al., 1992; van den
Ouweland et al., 1992). Experimental studies have demonstrated
that insulin secretion is critically dependent on mtDNA expres-
sion in pancreatic b cells (Silva et al., 2000). While several genes
with important functions in mitochondrial oxidative phosphoryla-
tion (OXPHOS) show reduced expression in patients with T2D,
only a few polymorphisms in these genes have been associated
with the disease (Ling et al., 2007a, 2008; Mootha et al., 2003;
Ro¨nn et al., 2008, 2009).
The OXPHOS system, including the electron transport system
(ETS) and ATP synthase, is located in the inner mitochondrial
membrane. It consists of multiprotein complexes with approxi-
mately 90 known subunits encoded by both the nuclear and
mitochondrial genomes (Scarpulla, 2008). The mitochondrial
genome, mtDNA, encodes 13 of the protein subunits present in
the ETS and ATP synthase as well as two rRNAs and 22 tRNAs.
Transcription of mtDNA requires a specialized machinery,
including factors necessary for promoter recognition, such as
mitochondrial transcription factor A (TFAM) and mitochondrial
transcription factor B2 (TFB2M) (Falkenberg et al., 2002; Litonin
et al., 2010; Metodiev et al., 2009; Scarpulla, 2008; Sologub
et al., 2009). Mitochondrial transcription factor B1 (TFB1M) is
a paralogue of TFB2M, but is probably not a transcription factor
(Litonin et al., 2010; Metodiev et al., 2009). Instead, TFB1M is
an essential methyltransferase that dimethylates two highly
conserved adenines present in a conserved stem-loop structure
at the 30 end of the 12S rRNA (Metodiev et al., 2009). The
Table 1. Clinical Characteristics of Participants in the Diabetes Genetics Initiative, DGI; the Prevalence, Prediction and Prevention of
Diabetes, Botnia PPP; the Helsinki Birth Cohort Study; the METabolic Syndrome In Men Study, METSIM; and the Malmo¨ Preventive
Project, MPP
DGI (Controls) DGI (T2D) Botnia PPP
Helsinki Birth
Cohort Study METSIM MPP
n (male/female) 1467 (707/760) 1464 (741/723) 4553 (2134/2419) 1618 (713/905) 6602 (6602/—) 16061 (10416/5645)
Age (years) 58.8 ± 10.1 64.4 ± 10.2 48.4 ± 15.6 61.6 ± 3.0 57.1 ± 6.9 45.5 ± 6.9
BMI (kg/m2) 26.6 ± 3.7 28.5 ± 4.5 26.3 ± 4.3 27.1 ± 4.3 26.8 ± 3.8 24.3 ± 3.3
Fasting plasma glucose
(mmol/l)
5.3 ± 0.5 9.5 ± 3.1 5.28 ± 0.57 5.49 ± 0.56 5.70 ± 0.49 5.45 ± 0.56
Glucose 30 min (mmol/l) 8.3 ± 1.5 13.3 ± 2.9 8.35 ± 1.55 9.10 ± 1.61 8.79 ± 1.43 9.97 ± 1.90
Glucose 120 min (mmol/l) 5.6 ± 1.3 14.7 ± 5.1 5.28 ± 1.64 6.88 ± 1.71 6.04 ± 1.68 6.39 ± 1.65
Fasting insulin (mU/l) 5.2 (4.3) 9.1 (9.0) 5.4 (4.2) 7.8 (6.5) 6.4 (5.7) —
Insulin 30 min (mU/l) 50.2 (48.9) 28.0 (35.7) 50.3 (38.4) 62.0 (50.2) 52.6 (46.8) —
Insulin 120 min (mU/l) 36.2 (29.7) 45.0 (50.3) 24.1 (26.7) 56.2 (56.6) 34.6 (42.6) —
Insulinogenic index 14.1 (14.8) 3.5 (5.2) 15.8 (16.0) 15.9 (15.9) 16.2 (16.6) —
Insulin sensitivity index (ISI) 8.6 (6.6) 3.8 (3.6) 8.0 (6.1) 5.0 (4.0) 6.2 (5.3) —
Data are expressed as mean ± SD or median (interquartile range [IQR]). See also Table S2.
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TFB1M Is a Pathogenetic Factor in T2Dmodification of 12S rRNA is essential for the integrity of the
small mitochondrial ribosomal subunit and mitochondrial
translation is abolished in its absence (Metodiev et al., 2009).
TFB1M is alternatively known as dimethyladenosine transferase
1 mitochondrial (mDMAT1) in protein databases.
In view of the important role of ATP production in metabolic
homeostasis, we examined whether polymorphisms in genes
of the OXPHOS system and the mtDNA transcription and trans-
lation machinery are associated with b cell dysfunction, insulin
resistance and/or T2D. To this end, we examined data from
a genome-wide association study (GWAS), the Diabetes
Genetics Initiative (DGI) (Saxena et al., 2007). We identified
a common variant (rs950994) in the human TFB1M gene, which
was associated with an impaired insulin response to glucose,
elevated glucose levels during an oral glucose tolerance test
(OGTT), increased future risk of T2D, and reduced islet TFB1M
expression. Accordingly, we proceeded to study mice with
a heterozygous deficiency of Tfb1m and clonal b cells, where
Tfb1m had been silenced to mimic the human situation. We
found that reduced levels of TFB1M caused impaired OXPHOS
and consequently decreased insulin secretion. This study
provides conclusive genetic and functional evidence that the
TFB1M gene is associated with increased risk of T2D by causing
impaired insulin secretion.
RESULTS
Identification of a Genetic Locus Associated
with Quantitative Metabolic Traits and T2D
To unravel genetic loci associated with b cell dysfunction, insulin
resistance, and/or T2D in or adjacent to genes of the OXPHOS
system and/or the mtDNA transcription and translation
machinery, we examined data from a GWAS, the DGI (Saxena
et al., 2007) (Table 1). We identified a common variant
(rs950994) in the gene encoding TFB1M, which was associated
with decreased insulin secretion at 30 min (insulinogenic index,
b = 0.17 ± 0.050, p = 0.0007), elevated 2 hr glucose levels
during an OGTT (b = 0.12 ± 0.042, p = 0.007) (Table 2), andCa nominally increased risk of T2D (odds ratio [OR] = 1.13, 95%
confidence interval [CI] = 1.02–1.25, p = 0.017) in DGI.
rs950994 is located in intron 2 of the TFB1M gene (Figure 1A
and Figure S1, available online).
Insulin Secretion and Postprandial Glucose Levels
In Vivo
Next, we examined whether the association of TFB1M rs950994
with impaired insulin secretion could be replicated in additional
cohorts (Tables 1 and 2). In accordance with the effect of
rs950994 in DGI, A-allele carriers of rs950994 showed
decreased insulinogenic index in the Botnia Prevalence, Predic-
tion and Prevention of Diabetes (Botnia PPP) study (b =0.045 ±
0.018, p = 0.01); this effect was stronger in elderly individuals
(age > median 50 yr, b = 0.085 ± 0.025, p = 0.001) (Table 2
and Table S1). In the METabolic Syndrome in Men (METSIM)
study and the Helsinki Birth Cohort Study (HBCS), rs950994
did not exert a significant effect on insulin secretion (Table 2).
Given that the METSIM study only included males, we asked
whether gender could affect the association of TFB1M
rs950994 with impaired insulin secretion. It is not uncommon
that gender is a determinant of genetic associations (Galimberti
et al., 2008; Joyner et al., 2009; Kolz et al., 2009; Miyashita et al.,
2007; Rimol et al., 2010), and metabolism in itself is known to be
influenced by sex hormones. Indeed, the A-allele of rs950994
was associated with decreased insulinogenic index in females
(Botnia PPP: b = 0.065 ± 0.024, p = 0.008; DGI: b =0.20 ±
0.06, p = 0.0005), but not in males (Botnia PPP: p = 0.46 and
DGI: p = 0.10) (Table 2). In line with this finding, gender-stratified
meta-analysis of all studied cohorts supported an association
between rs950994 and insulinogenic index in females (p = 0.006,
Pheterogeneity = 0.059), but not in males (p = 0.79, Pheterogeneity =
0.072) (Figures S2A and S2B). Similar to the gender effect of
rs950994 on insulin secretion, an association of rs950994 with
postprandial (2 hr) glucose levels was only observed in females
from Botnia PPP (b = 0.019 ± 0.009, p = 0.03) and DGI (b =
0.13 ± 0.07, p = 0.06) (Table 2). A meta-analysis further strength-
ened the association between rs950994 and 2 hr plasma glucoseell Metabolism 13, 80–91, January 5, 2011 ª2011 Elsevier Inc. 81
Table 2. TFB1M rs950994 in Relation to Postprandial Glucose Levels and Insulin Secretion in Nondiabetic Individuals of the Studied
Cohorts
Genotypes Additive Model
Study Phenotype GG GA AA RA Beta SEM p value
DGI (n = 894) Insulinogenic index 15.9 (18.4) 14.4 (14.8) 12.5 (11.0) 0.28 0.17 0.050 0.0007
(n = 1286) Glucose 2 hr (mmol/l) 5.60 ± 1.26 5.67 ± 1.29 5.96 ± 1.21 0.12 0.042 0.007
DGI (females, n = 471) Insulinogenic index 17.9 (20.4) 14.0 (15.2) 13.0 (12.6) 0.28 0.20 0.057 0.0005
(n = 674) Glucose 2 hr (mmol/l) 5.75 ± 1.20 5.86 ± 1.30 6.08 ± 1.15 0.13 0.071 0.062
DGI (males, n = 423) Insulinogenic index 14.1 (17.7) 14.9 (14.1) 11.0 (10.4) 0.28 0.098 0.060 0.10
(n = 612) Glucose 2 hr (mmol/l) 5.42 ± 1.32 5.48 ± 1.25 5.82 ± 1.29 0.098 0.083 0.24
Botnia PPP (n = 4290) Insulinogenic index 16.5 (17.0) 15.5 (15.6) 14.6 (13.8) 0.31 0.045 0.018 0.010
Glucose 2 hr (mmol/l) 5.20 ± 1.64 5.24 ± 1.62 5.34 ± 1.66 0.011 0.007 0.10
Botnia PPP (females, n = 2260) Insulinogenic index 17.3 (17.8) 16.3 (16.6) 14.7 (14.2) 0.31 0.065 0.024 0.008
Glucose 2 hr (mmol/l) 5.28 ± 1.49 5.37 ± 1.56 5.51 ± 1.47 0.019 0.009 0.030
Botnia PPP (males, n = 2026) Insulinogenic index 15.8 (16.2) 14.8 (14.6) 14.3 (13.3) 0.30 0.019 0.025 0.46
Glucose 2 hr (mmol/l) 5.13 ± 1.79 5.09 ± 1.67 5.15 ± 1.84 0.004 0.011 0.68
HBCS (n = 1561) Insulinogenic index 16.0 (15.6) 15.8 (16.3) 14.0 (15.1) 0.27 0.0003 0.029 0.99
Glucose 2 hr (mmol/l) 6.86 ± 1.74 6.84 ± 1.66 7.13 ± 1.62 0.013 0.010 0.19
HBCS (females, n = 866) Insulinogenic index 16.7 (15.7) 15.6 (16.3) 15.0 (15.2) 0.27 0.006 0.039 0.87
Glucose 2 hr (mmol/l) 6.89 ± 1.66 7.01 ± 1.64 7.25 ± 1.65 0.019 0.013 0.14
HBCS (males, n = 695) Insulinogenic index 15.7 (15.3) 15.9 (16.2) 12.4 (13.3) 0.27 0.001 0.043 0.99
Glucose 2 hr (mmol/l) 6.81 ± 1.82 6.64 ± 1.66 6.99 ± 1.57 0.007 0.016 0.66
METSIM (n = 5400) Insulinogenic index 15.6 (15.5) 16.2 (16.9) 16.0 (17.9) 0.31 0.019 0.015 0.20
Glucose 2 hr (mmol/l) 6.10 ± 1.71 6.06 ± 1.65 6.21 ± 1.76 0.004 0.006 0.53
MPP (n = 8778) Glucose 2 hr (mmol/l) 6.40 ± 1.64 6.37 ± 1.66 6.39 ± 1.68 0.32 0.022 0.024 0.35
MPP (females, n = 3096) Glucose 2 hr (mmol/l) 7.28 ± 1.59 7.23 ± 1.57 7.30 ± 1.58 0.019 0.042 0.66
MPP (males, n = 5681) Glucose 2 hr (mmol/l) 5.93 ± 1.47 5.90 ± 1.50 5.87 ± 1.50 0.016 0.029 0.58
Data are expressed asmean ± SD or asmedian (IQR). b (SEM) are from linear regression adjusted for age, sex, and BMI. RA is the risk allele frequency.
p values < 0.05 are shown in bold. See also Figure S2.
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TFB1M Is a Pathogenetic Factor in T2Din females (b = 0.019 ± 0.007, p = 0.008, Pheterogeneity = 0.175)
(Figure S2C), while no association was observed in males (p =
0.43) (Figure S2D).
Insulin Sensitivity In Vivo
Mitochondrial metabolism has also been implicated in insulin
sensitivity in peripheral tissues (Ling et al., 2004, 2007a; Ro¨nn
et al., 2008, 2009). Therefore, we tested whether the TFB1M
variant rs950994 influenced insulin sensitivity in vivo during a
hyperinsulinemic euglycemic clamp in twins. Here, female
A-allele carriers showed reduced insulin-stimulated glucose
uptake (Rd) during the clamp (G/G: 12.6 ± 0.5, n = 43 versus
A/A + A/G: 10.4 ± 0.4, n = 50, p = 0.003), while no association
was observed in male twins (G/G: 10.5 ± 0.5, n = 40 versus
A/A + A/G: 10.3 ± 0.5, n = 56, p = 0.65). However, there was
no significant association between rs950994 and insulin sensi-
tivity index (ISI) during the OGTT in the studied cohorts, regard-
less of gender (Table S2).
Risk of T2D
After having established that the TFB1M single nucleotide poly-
morphism (SNP) rs950994 is associated with T2D-related traits,
we asked whether the TFB1M SNP rs950994 could predict
future T2D. To this end, we examined 16,061 Swedish subjects
in a prospective study, the Malmo¨ Preventive Project (MPP);82 Cell Metabolism 13, 80–91, January 5, 2011 ª2011 Elsevier Inc.2,063 of the individuals developed diabetes during the median
25-year follow-up period (Table 1). The frequency of the risk
A-allele of SNP rs950994 was higher in individuals who devel-
oped T2D compared to those who did not (34.1% versus
31.9%, p = 0.006). This yielded a modestly increased risk of
T2D with an OR of 1.12 (95% CI = 1.04–1.20, p = 0.002). The
observed effect on future risk of T2D was of a magnitude similar
to the associationwith T2D observed in DGI (Saxena et al., 2007).
Furthermore, the TFB1M SNP rs950994 was an independent
predictor of risk for T2D (OR = 1.11, 95% CI = 1.03–1.20, p =
0.005) in the multivariate regression analyses with a genetic
risk score comprising 11 established genetic loci previously
reported to be associated with increased risk of T2D in the
MPP cohort (Lyssenko et al., 2008) (Table S3).
TFB1M Gene Expression and Insulin Secretion
in Pancreatic Islets
To identify a mechanism whereby the risk variant of TFB1M
contributes to the development of T2D, we examined whether
rs950994 was associated with altered gene expression in human
pancreatic islets by using quantitative real time-polymerase
chain reaction (RT-PCR). Risk A-allele carriers of rs950994
showed a 24% reduction in TFB1M expression compared
with GG carriers (n = 50, p = 0.005 for a dominant and p =
0.001 for an additive genetic model, respectively) (Figure 1B).
Figure 1. Effects of rs950994 on Human
Pancreatic Islets
(A) Map of the human TFB1M gene; rs950994
(arrow) is located in intron 2 of the gene (see also
Figure S1).
(B) TFB1M mRNA levels were lower in pancreatic
islets from risk A-allele carriers (n = 24) compared
with G/G carriers (n = 26) of TFB1M SNP rs950994
based on a dominant model (** < 0.01). Bars repre-
sent mean ± standard deviation (SD).
(C) Representative western blots and densito-
metric analysis of protein levels for TFB1M from
four G/G carriers (white bar) and four risk A-allele
carriers (black bars) of rs950994 (* < 0.05). Bars
represent mean ± standard error of the mean
(SEM).
(D) Representative western blots of protein levels
for mitochondrially encoded ND1 (complex I),
ND5 (complex I), and COX1 (complex IV) and
nuclear-encoded NDUFB8 (complex I), QCR2
(complex III core protein 2), and ATPA (ATP syn-
thase F1 subunit a) in pancreatic islets from four
G/G carriers and four risk A-allele carriers of
rs950994.
(E) Densitometric analysis of protein levels in
pancreatic islets from four G/G carriers (white
bar) and four risk A-allele carriers (black bars) of
rs950994 (* < 0.05). Bars represent mean ± SEM.
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TFB1M Is a Pathogenetic Factor in T2DMoreover, the mRNA levels of TFB1M correlated positively with
glucose-stimulated insulin secretion (GSIS) in pancreatic islets
from human donors challenged with glucose in vitro (r = 0.40,
p < 0.05).
To examine whether reducedmRNA levels of TFB1M translate
into reduced protein levels, we analyzed TFB1M andmitochond-
rially encoded subunits of complex I (ND1, ND5) and complex IV
(COX1) as well as nuclear-encoded subunits of complex I
(NDUFB8), complex III (QCR2), and ATP synthase (ATPA) in
a subset of human islets. This subset of donors included four
GG carriers and four A-allele carriers of rs950994; in islets from
these risk-allele carriers, TFB1M mRNA levels were decreased
by 44% (G/G: 1.46 ± 0.06, n = 4 versus A/G + A/A: 0.82 ± 0.19,
n = 4, p = 0.02). Indeed, the protein levels of TFB1M (G/G:
1.00 ± 0.14 versus A/G + A/A: 0.55 ± 0.04, p = 0.02), ND1
(G/G: 1.00 ± 0.31 versus A/G + A/A: 0.31 ± 0.08, p = 0.02), and
ND5 (G/G 1.00 ± 0.19 versus A/G + A/A 0.26 ± 0.08, p = 0.01)
were significantly decreased in the A-allele carriers of this subset
of donors, whereas those of NDUFB8 (p = 0.3), QCR2 (p = 0.3),
COX1 (p = 0.16), and ATPA (p = 0.1) were not significantly
changed (Figures 1C–1E). These findings suggest that reducedCell Metabolism 13, 80–levels of TFB1M mRNA and protein in
human islets are associated with reduc-
tions inmitochondrially encoded subunits
of complex I.
TFB1M Deficiency, Insulin
Secretion, and Mitochondrial
Metabolism in Mice
To further elucidate the mechanisms
whereby reduced expression of TFB1Mmay contribute to b cell failure and the development of T2D,
we examinedmice heterozygous (Tfb1m+/) for a germ-line dele-
tion of Tfb1m (Metodiev et al., 2009). The rationale for this
approach is that a reduction of TFB1M expression would mimic
the situation in humans, whereas total deficiency is known to be
embryonically lethal (Metodiev et al., 2009). Indeed, islets from
Tfb1m+/ mice contained less TFB1M protein than their wild-
type littermates (Figure 2A), confirming that these mice would
be a suitable model to study the role of TFB1M in metabolic
dysregulation.
First, the Tfb1m+/ mice were subjected to an intraperitoneal
glucose tolerance test (IPGTT) to examine glucose tolerance
and insulin secretion in vivo. We found that plasma glucose
levels rose to higher levels in the Tfb1m+/ mice during
the glucose challenge (16.1 ± 0.7 versus 18.7 ± 0.7 mM glucose,
t = 10 min, p = 0.02; 16.5 ± 1.1 versus 19.5 ± 0.8 mM glucose, t =
30 min, p = 0.02; 14.2 ± 0.6 versus 16.2 ± 0.6 mM glucose,
t = 60 min, p = 0.04; 1754 ± 65 versus 1984 ± 70, glucose-area
under the curve [glcAUC], p = 0.01 in control versus Tfb1m
+/
mice, respectively; Figure 2B). At the same time insulin secretion
tended to be lower, albeit not significantly different, in the91, January 5, 2011 ª2011 Elsevier Inc. 83
Figure 2. Reduced TFB1M Levels in Heterozygous Mice (Tfb1m+/–) Result in Impaired Stimulated Insulin Secretion
(A) Pancreatic islets from heterozygous mice (Tfb1m+/) were used to test the effect of TFB1M deficiency. Fresh isolated pancreatic islets were subjected to
analysis. Representative western blot and densitometric analysis of TFB1M protein levels in the Tfb1m+/+ (n = 4) and Tfb1m+/ (n = 4) mice are shown.
(B and C) Plasma glucose (B) and (C) plasma insulin levels in the Tfb1m+/+ (n = 10) and Tfb1m+/ (n = 11) mice during an IPGTT.
(D) The insulin-area-under-the-curve (insAUC)/glucose-area-under-the-curve (glcAUC) ratio for the Tfb1m
+/+ (n = 10) and Tfb1m+/ (n = 11) mice during the IPGTT
reflects the capacity of the mice to release insulin in response to glucose.
(E) Insulin secretion in response to 2.8 and 16.7 mM glucose (Glc) (n = 12–15) and 10 mM a-KIC in the presence of 2.8 mM glucose (n = 13–15) was determined in
a 1 hr static incubation of the pancreatic islets from Tfb1m+/+ and Tfb1m+/ mice.
(F) Representative western blot from the same samples as for TFB1M in (A) (therefore with the same loading control) and densitometric analysis of ND5 protein
levels (complex I, mitochondrially encoded) in pancreatic islets from Tfb1m+/+ (n = 4) and Tfb1m+/ (n = 4) mice .
(G) Kinetics of ATP production were determined in digitonin-permeabilized islets from Tfb1m+/+ (n = 6) and Tfb1m+/ (n = 6) mice in response to a mixture of
pyruvate, glutamate, and malate. Bars represent mean ± SEM (* < 0.05; ** < 0.01). See also Table S4.
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TFB1M Is a Pathogenetic Factor in T2DTfb1m+/mice compared with wild-type littermates (t = 120 min,
p = 0.07; insulin-area under curve [insAUC], p = 0.12; Fig-
ure 2C). However, when total insulin secretion during the chal-
lenge (insAUC) was related to the rise in glucose (glcAUC), we
found that this ratio was decreased in Tfb1m+/ mice (44.5 ±
3.0 versus 32.5 ± 4.1, p = 0.03 in control versus Tfb1m+/
mice, respectively; Figure 2D). This implies that insulin secretion
was insufficient to meet the demands of the glucose challenge
in the Tfb1m+/ mice; hence, elimination of glucose was dimin-
ished. These results demonstrate that TFB1M deficiency is
associated with glucose intolerance and impaired insulin secre-
tion. If the Tfb1m+/ mice had a sufficient insulin secretory
capacity, they would have compensated with increased insulin
secretion.84 Cell Metabolism 13, 80–91, January 5, 2011 ª2011 Elsevier Inc.To further understand whether this in vivo perturbation was
caused by islet dysfunction and impairedmitochondrial function,
we isolated islets from the genetically manipulated mice. We
found that insulin secretion in response to glucose was attenu-
ated in islets from the Tfb1m+/ mice (1.36 ± 0.19 versus
0.87 ± 0.14 ng insulin/islet/hr, p = 0.04 in control versus Tfb1m+/
mice, respectively; Figure 2E). Moreover, insulin secretion in
response to a-ketoisocaproic acid (a-KIC), a secretagogue that
directly stimulates mitochondrial metabolism, was markedly
reduced (2.28 ± 0.32 versus 1.07 ± 0.13 ng insulin/islet/hr, p =
0.001 in control versus Tfb1m+/ mice, respectively; Figure 2E),
while that in response to 35 mM KCl, a membrane-depolarizing
agent, was unaffected (0.47 ± 0.20 versus 0.45 ± 0.12 ng
insulin/islet/hr in the presence of 2.8 mM glucose in control
Figure 3. Reduced TFB1M levels in Clonal b Cells Result in Impaired
Insulin Secretion
(A) Glucose-sensitive clonal b cells (INS 832/13) were used to examine the
consequences of TFB1M deficiency. Ninety-six hours after transfection with
siRNA to Tfb1m, cells were subjected to analysis. mRNA levels for Tfb1m
were analyzed by quantitative polymerase chain reaction (Q-PCR) in control
cells (siNC) and cells where Tfb1m had been silenced (siTFB1M) (n = 3).
(B) Densitometric analysis of western blots for TFB1M (n = 4).
(C) Insulin secretion in response to 2.8 and 16.7 mM glucose (Glc) (n = 10) and
10 mM a-KIC in the presence of 2.8 mM glucose (n = 4) and 35 mM potassium
chloride (KCl) in the presence of 250 mM diazoxide (n = 3) was determined in
a 1 hr static incubation of the 832/13 b cells. Bars represent mean ± SEM
(* < 0.05; ** < 0.01). See also Table S1.
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TFB1M Is a Pathogenetic Factor in T2Dversus Tfb1m+/ mice, respectively). These data together sug-
gest that impaired insulin secretion in Tfb1m+/ mice is caused
by perturbed mitochondrial function. To confirm this, we
analyzed levels of ND5 in isolated islets. Western blot analysis
showed that the level of ND5 was lower in mitochondria from
Tfb1m+/ mice (Figure 2F), reflecting the observation we made
in islets from human risk-allele carriers (Figures 1D and 1E).
Finally, we assayed the kinetics of ATP production, which is
the final and essential product of mitochondrial metabolism
and which controls insulin secretion via closure of the KATP
channels. Indeed, the rate of ATP production in permeabilized
isolated islets in response to a mixture of the mitochondrial
metabolic substrates pyruvate, glutamate, and malate was
significantly reduced in Tfb1m+/ mice (34.1 ± 2.5 versus 25.4 ±
0.9 pmol ATP/min/islet, p = 0.04 in control versus Tfb1m+/mice,
respectively; Figure 2G). We conclude that mimicking the
deficiency of TFB1M occurring in the human in mice leads to
glucose intolerance, impaired mitochondrial function, and per-
turbed fuel-stimulated insulin secretion.
Silencing of TFB1M in Clonal b Cells
To further model the situation in human and mouse islets and
identify mechanisms whereby reduced expression of TFB1M
may compromise mitochondrial function and insulin secretion,
we silenced Tfb1m in the glucose-responsive 832/13 clonal
b cell line with small interfering RNAs (siRNA). First, using
RT-PCR and western blotting, we analyzed expression of
TFB1M after silencing. We found a reduction in the Tfb1m
mRNA level to 24.2% ± 0.6% (p = 0.0001; Figure 3A), and in
protein level to 44.2% ± 1.8% of control (p = 0.0006; Figure 3B)
after transfection with siRNA directed to Tfb1m for 96 hr. Similar
to human and mouse islets, TFB1M deficiency in clonal b cells
leads to a reduction in GSIS (181.5 ± 5.5 versus 110.0 ±
5.2 ng/mg/hr, p < 0.001 in control cells versus TFB1M-deficient
cells, respectively; Figure 3C) as well as in insulin secretion
in response to a-KIC (116.0 ± 9.3 versus 55.0 ± 5.2 ng/mg/hr,
p = 0.001 in control cells versus TFB1M-deficient cells, respec-
tively; Figure 3C). As in isolatedmouse islets, the response to KCl
was not significantly affected (Figure 3C), indicating that there
was no unspecific perturbation of the exocytotic machinery or
loss of insulin from the clonal b cells. The latter was confirmed
by measurement of cellular insulin content after 96 hr of
TFB1M knockdown (8.8 ± 0.4 versus 8.2 ± 0.5 mg/mg in control
cells versus TFB1M-deficient cells, respectively).
Because the perturbation of insulin secretion stimulated by
metabolic substrates in mouse islets and clonal b cells sug-
gested that TFB1M deficiency disrupted only the mitochondrial
control of stimulus-secretion coupling (Henquin, 2009) and given
that TFB1M is thought to primarily control translation of mito-
chondrially encoded proteins (Metodiev et al., 2009), we further
examined OXPHOS protein levels in mitochondria from the
clonal b cells. Using a panel of selected antibodies to both
mitochondrially and nuclear-encoded proteins for western blot-
ting, we found decreased levels of OXPHOS proteins in b cells
where TFB1M had been silenced (Figure 4A). While the levels
of both assayed subunits of complex I, the mitochondrially
encoded ND5, and the nuclear-encoded NDUFB8 were signifi-
cantly reduced, only the mitochondrially encoded subunits of
complex III, Cyt b, and of complex IV, COX1, showed signifi-Ccantly reduced protein levels in cells with TFB1M deficiency.
This may be explained by the particularly crucial function of the
mitochondrially encoded subunits during the modular assembly
of complex I (Cardol et al., 2002; Chomyn, 2001; Perales-Clem-
ente et al., 2010). Thus, reduced levels of both mitochondriallyell Metabolism 13, 80–91, January 5, 2011 ª2011 Elsevier Inc. 85
Figure 4. Reduced TFB1M Levels in Clonal b Cells Result in Impaired Mitochondrial OXPHOS and ATP Generation
(A) Clonal b cells (INS 832/13) were used to test the effect of TFB1M deficiency. Ninety-six hours after transfection with siRNA to Tfb1m, cells were subjected to
analysis. White bars represent control (siNC) and black bars represent siTFB1M. Representative western blots and densitometric analysis of protein levels for
NDUFB8 (complex I, nuclear encoded), ND5 (complex I, mitochondrially encoded), succinate dehydrogenase complex, subunit B, iron sulfur (SDHB, complex
II, nuclear encoded), QCR2 (complex III core protein 2, nuclear encoded), Cyt b (complex III, mitochondrially encoded), COX1 (complex IV, mitochondrially en-
coded), and ATPA (ATP synthase F1 subunit a, nuclear encoded) (n = 4).
(B) Relative ETS complexes I, III, and IV and ATP synthase activities in cells where TFB1M had been silenced and normalized to the activities of each control (n = 8
for ETS complexes and 4 for ATP synthase).
(C) Analysis of oxygen consumption rates (OCR): Cells were preincubated at 2.8mMglucose for 2 hr. ThenOCRsweremeasured at 2.8mM followed bymeasure-
ments at 16.7 mM after glucose injection at time point 1. At time point 2, oligomycin, an inhibitor of ATP synthase was added; at time point 3, dinitrophenol, an
uncoupler was added, followed by the addition of rotenone at time point 4, an inhibitor of complex 1. P, L, and E indicate the areas for further analysis (white
squares represent siNC, black ones siTFB1M) (n = 4).
(D) Time-normalized area-under-the-curve analysis of OCR measurements calculating coupled OXPHOS capacity (P, excess ADP), proton-leak oxygen flux
(L, ADP consumed), and uncoupled total electron transport capacity (area E, uncoupled).
(E) Calculated mitochondrial function parameters based on area-under- the-curve analysis: respiratory-control ratio (RCR = P/L) and leak-flux-control ratio
(LFCR = L/E).
(F) Accumulation of cellular ATPwas determined in 832/13 b cells upon a 1 hr stimulation by 2.8mMglucose (Glc), 16.7mMGlc, or 16.7mMGlc in the presence of
DNP and oligomycin (n = 4). Bars represent mean ± SEM. * < 0.05; ** < 0.01. See also Table S3.
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the assembly of complex I is disrupted because of the TFB1M
deficiency. In contrast, protein levels of complex II, with all
subunits encoded in the nucleus, were unaffected. Also, the
citrate synthase activity was unchanged (122.8 ± 3.4 versus
118.6 ± 4.9 mmol citrate/min/mg in control cells versus TFB1M-
deficient cells, respectively). This suggests that mitochondrial
biogenesis was unaffected by TFB1M deficiency for 96 hr in
the studied cell line.
The negative impact of TFB1M deficiency on respiratory
proteins was further corroborated by activity determinations in
ETS complexes I, III, and IV as well as of ATP synthase in mito-
chondria-enriched subcellular fractions. While activities of all
these enzyme complexes were reduced when TFB1M had
been silenced, complex I activity was, as predicted by the
protein expression levels, most profoundly impaired by TFB1M
knockdown (3.98 ± 0.26 versus 1.73 ± 0.15 mmol/min/mg, p <
0.001 in control cells versus TFB1M-deficient cells; Figure 4B).
Next, we examined the functional consequences of the
observed OXPHOS protein and activity perturbations in
TFB1M-silenced b cells. The measurement of O2 consumption
by cytochrome C oxidase (complex IV) is commonly used to
assess the activity of mitochondrial ETS and OXPHOS. To this
end, we measured O2 consumption in the SeahorseXF24 Extra-
cellular Flux Analyzer. The basal (2.8 mM glucose), stimulated
(16.7 mM glucose; P) and uncoupled (40 mM 2,4-dinitrophenol
[2,4-DNP]; E) O2 consumption rates (OCR) were reduced by
18.3% ± 0.5%, 22.0% ± 0.2%, and 24.5% ± 2.7%, respectively,
in cells where TFB1M had been silenced (Figure 4C). A time-
normalized area-under-the-curve analysis further confirmed
this conclusion. Here, we found that TFB1M deficiency caused
significant decreases in the coupled OCR (area P: 11.0 ± 0.3
versus 8.9 ± 0.4 nmol O2/min/mg, p = 0.004 in control
cells versus TFB1M-deficient cells) and the uncoupled OCR
(area E: 15.5 ± 0.5 versus 12.1 ± 0.9 nmol O2/min/mg, p = 0.01
in control cells versus TFB1M-deficient cells) (Figure 4D). This
analysis further revealed a decreased ADP-stimulated OCR,
which was calculated as the difference between the coupled
OCR, P, and the basal OCR (basal oxygen consumption without
ADP addition or uncoupling), L (4.9 ± 0.4 versus 3.3 ± 0.2 nmol
O2/min/mg, p = 0.01 in control compared to TFB1M-deficient
cells). The analysis also revealed a TFB1M-dependent decrease
in the respiratory-control ratio (RCR) and an increase in the leak-
flux-control ratio (LFCR), both indicating decreased coupling
between electron transport and ATP synthesis (Figure 4E).
The final step in mitochondrial metabolism-linked OXPHOS
is production of ATP, which is also established as the trigger
of GSIS. Therefore, we analyzed whether the mitochondrial
perturbations that we have described in TFB1M deficiency also
affected the kinetics of mitochondrial ATP production in
response to the same metabolic substrate mixture that was
used for this analysis in mouse islets and the cellular ATP
level at the end of GSIS (16.7 mM). Indeed, we found a 29.3% ±
0.5% decrease in the kinetics of mitochondrial ATP production
(10.3 ± 0.2 versus 7.3 ± 0.3 nmol ATP/min/mg, n = 4, p =
0.0002 in control compared to TFB1M-silenced cells) and
a 27.6% ± 4.8% decrease in the glucose-induced cellular ATP
level (p = 0.01; Figure 4F) in the TFB1M-deficient cells. We
confirmed that TFB1M knockdown did not affect the ATP levelsCin unstimulated cells and in cells treated with 2,4-DNP and oligo-
mycin (Figure 4F). These compounds dissipate themitochondrial
membrane potential and block ATP synthase, respectively,
thereby abolishing mitochondrial ATP synthesis. This indicates
that the observed decrease in cellular ATP caused by TFB1M
silencing is entirely because of impaired mitochondrial, and not
glycolytic, ATP synthesis. Thus, in sum, the data show that
impaired insulin secretion in TFB1M-deficient b cells is caused
by perturbed OXPHOS.
TFB1M Gene Expression in Human Skeletal Muscle
Mitochondrial metabolism has also been implicated in control of
insulin sensitivity and female A-allele carriers of rs950994
showed reduced Rd during a clamp. Therefore, we analyzed
TFB1M mRNA expression in skeletal muscle from the twins. In
agreement with the gender effect of rs950994 on insulin sensi-
tivity during the clamp, female A-allele carriers showed reduced
TFB1M expression in muscle (G/G: 0.26 ± 0.009, n = 42 versus
A/A + A/G: 0.23 ± 0.008, n = 39, p = 0.05), whereas male twins
did not (G/G: 0.29 ± 0.015, n = 35 versus A/A + A/G: 0.30 ±
0.013, n = 49, p = 0.7). Furthermore, while TFB1M expression
was reduced by 13% (p = 0.003) in muscle from elderly (age
62.4 ± 0.2 yr) compared with young (age 28.0 ± 0.2 yr) female
twins, no effect of age was seen in male twins (p = 0.3). We
also found a positive association (p = 0.01) between insulin
sensitivity in vivo and TFB1M expression in muscle (Table S4).
mtDNA Copy Number
Our study shows that reduced levels of TFB1M result in impaired
OXPHOS. However, whether the mitochondrial number is
changed in subjects carrying the risk allele of rs950994 remains
unknown. We therefore tested whether rs950994 was associ-
ated with mtDNA copy number in blood cells from a subset of
the Botnia cohort (n = 467). Although the effect size was small,
mtDNA copy number was lower in A-allele carriers of rs950994
(p = 0.009) (Figure S3A). When stratifying the analysis for gender,
rs950994 was associated with mtDNA copy number in females
(p = 0.005), but not in males (p = 0.34) (Figure S3B).
DISCUSSION
Mitochondria are at center stage in cellular metabolism and
hence play a critical role in the pathogenic processes leading
to many diseases, particularly metabolic disorders (Goto et al.,
1990; Kelley et al., 2002; Petersen et al., 2003, 2004; Reardon
et al., 1992; van den Ouweland et al., 1992). Here, we present
genetic, clinical, and experimental in vivo and in vitro evidence
that a polymorphism in TFB1M, a nuclear-encoded factor
involved in translational control in mitochondria (Falkenberg
et al., 2002; Metodiev et al., 2009), is associated with impaired
insulin secretion, elevated postprandial glucose levels, and T2D.
Mining the DGI GWAS for genes involved in OXPHOS led to
identification of the association between rs950994 and T2D,
and subsequently to the discovery that this polymorphism is
associated with an increased future risk of T2D in the prospec-
tive MPP study. The effect of rs950994 on future risk of T2D is
of a magnitude similar to the associations with T2D previously
observed for approximately 20 SNPs (Lyssenko et al., 2008,
2009; Saxena et al., 2007). Together, these studies demonstrateell Metabolism 13, 80–91, January 5, 2011 ª2011 Elsevier Inc. 87
Figure 5. Model for a Possible Role of TFB1M in the Development of T2D
Our data suggest a model where the risk SNP confers lower TFB1M protein expression. Consequently, protein synthesis is impaired. As a consequence of
reduced synthesis of mitochondrially encoded proteins, OXPHOS is restrained, reducing ATP production and hence stimulus-secretion coupling in the b cell
is abrogated (see also Figure S3).
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play a role. rs950994 was also associated with elevated post-
prandial glucose levels during OGTTs in the DGI. The elevation
of plasma glucose and association with T2D are probably
accounted for by impaired insulin secretion, because the
insulinogenic index was significantly reduced in risk-allele
carriers of rs950994. However, a concomitant influence of
impaired peripheral insulin action as demonstrated in female
twin carriers of the risk allele cannot be excluded. The patho-
genic role of TFB1M was further suggested by the fact that
carriers of the risk allele showed a reduction in islet TFB1M
expression and that expression of TFB1M correlated with the
insulin response to glucose in isolated human islets as well as
with protein levels of mitochondrially encoded OXPHOS
complexes. Introducing the A of the risk allele instead of a G
because of rs950994 disrupts several putative transcription
factor binding sites in intron 2 of TFB1M, which may affect the
expression of TFB1M. Accordingly, variable expression in
different cell types of these putative transcription factors may
explain why TFB1M mRNA expression was reduced in human
pancreatic islets and skeletal muscle but unaltered in adipose
tissue (data not shown).
To find further support for the role of TFB1M in the pathogen-
esis of T2D and to resolve pathogenic processes, we examined
a mouse model for TFB1M deficiency. The Tfb1m+/ mice were
chosen because they exhibited reduced, but not lacking,
expression of TFB1M (Metodiev et al., 2009), which resembles
the situation in human A-allele carriers of rs950994. Indeed,
the Tfb1m+/ mice displayed many features similar to those
found in the human cohorts with metabolic traits associated
with TFB1M rs950994. All features of Tfb1m+/ mice assessed
in this study point to impaired mitochondrial function as the
cause of glucose intolerance via impaired insulin secretion.
This is probably explained by insufficient regulatory actions of
TFB1M on the translation of mitochondrially encoded OXPHOS
protein subunits in islet b cell mitochondria.
To further elucidate the impact of TFB1M deficiency on mito-
chondrial function in b cells and therefore on pathogenic
processes underlying the diabetogenic properties of the
rs950994 polymorphism, we also performed in vitro studies in
clonalb cells. These experimentswerebasedonour observations
that the risk-allele carriers exhibited reduced expression of
TFB1M in human islets. Using siRNA to reduce TFB1M
protein levels,weconfirmed theassociationofmultiple abnormal-
ities in the OXPHOS system and therefore of impaired metabo-88 Cell Metabolism 13, 80–91, January 5, 2011 ª2011 Elsevier Inc.lism-coupled mitochondrial ATP generation with TFB1M
deficiency. Our ETS complex activity measurements together
with the western blot data propose that perturbations of
complex I may play a particularly important role in TFB1M defi-
ciency. However, although TFB1M deficiency resulted in a
substantial decline in complex I protein and activity levels, the
reductions in OCR, ATP production, and GSIS were less
profound, albeit significant. This suggests that there is an
overcapacity of the OXPHOS system, which prevents frank mito-
chondrial disease but not a restraining effect on b cell stimulus-
secretion coupling. Alternatively, because complex II protein
levels were unchanged upon TFB1Mdeficiency, the use of succi-
nate as a substrate for the ETSmay to some extent also compen-
sate for the lowcomplex I activity (Cimenet al., 2010). All together,
the observeddefects are likely to include not only changes in indi-
vidualOXPHOScomplexesbut also the functional coordinationof
the whole system. Hence, insulin secretion in response to meta-
bolic fuels (e.g., glucose and a-KIC) was impaired.
All our data collected from humans, mice, and clonal b cells
converge into the recognition of a mitochondrial OXPHOS
defect associated with the rs950994 polymorphism, which
accounts for the impairment of insulin secretion.Ourdata suggest
a model where this risk SNP confers lower TFB1M expression.
Consequently, mitochondrial protein synthesis is impaired, re-
straining OXPHOS, and hence stimulus-secretion coupling in
thebcell is abrogated (Figure 5). Indeed,we found thatATP levels,
known to be the trigger of insulin secretion (Henquin, 2009), were
reduced both in Tfb1m+/mice and in clonal b cells where TFB1M
hadbeensilenced.Thismirrors findings in islets fromhumanswith
T2D, which exhibit lower ATP levels and impaired hyperpolariza-
tion of the inner mitochondrial membrane (Anello et al., 2005),
a process that normally occurs in response to elevated glucose.
Also, recent studies in a mouse model of T2D, the MKR mouse,
demonstrate the evolution of mitochondrial defects during the
progression to diabetes (Lu et al., 2010).
A remarkable finding in our study is that the pathogenic effect
of the genetic variant, to a large extent, seems to depend on
gender. Accordingly, no effect of the rs950994 polymorphism
was observed in the METSIM study, which was comprised of
males only. Moreover, the association of the risk allele with
insulinogenic index was lost in the male contingent both in the
DGI GWAS and the Botnia PPP study when the subjects were
stratified for gender. Similarly, the association of rs950994 with
Rd was only found in the female twins. Although it is not
uncommon that gender influences genetic associations (Joyner
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studies are needed to further dissect the molecular mechanisms
underlying the gender-specific effects of rs950994. In addition,
age also seems to affect the association of TFB1M with various
parameters analyzed in the study. In agreement with previous
studies, this emphasizes the important role of aging in the devel-
opment of mitochondrial dysfunction and T2D (Larsson, 2010;
Ling et al., 2004, 2007a; Ro¨nn et al., 2008, 2009).
Clearly, mitochondrial metabolism also plays an important role
for glucose homeostasis in target tissues of insulin (Kelley et al.,
2002; Ritov et al., 2005). We have previously proposed that
genetic and epigenetic regulation of mitochondrial function
increase susceptibility for insulin resistance with increasing age
(Ling et al., 2004, 2007a, 2007b; Ro¨nn et al., 2008, 2009). Here,
a dysfunctional phenotype in insulin target tissues was apparent
but not pronounced. Although an association between rs950994
and Rd was found during clamp studies in female twins, associ-
ations of the risk allele with insulin sensitivity measures during
OGTTs were lacking. This may be because of the fact that the
clamp technique is more sensitive and specific than an OGTT
for analyzing insulin sensitivity.
In summary, TFB1M can be added to the growing list of
genes implicated in the risk of developing T2D. Its pathogenic
role is not difficult to understand, given the critical role of mito-
chondrial function in control of insulin secretion from the pancre-
atic b cell and in the target tissues of the hormone. In fact, the
dysregulation of mtDNA has previously been implicated in the
pathogenesis of T2D, because genetic inactivation of Tfam in
mouse b cells leads to impaired insulin secretion and diabetes
(Silva et al., 2000). Moreover, deficiency of Pdx1, a crucial tran-
scription factor in pancreatic b cells, causes mitochondrial
dysfunction and defective insulin secretion in mice and clonal
b cells because of suppression of Tfam expression (Gauthier
et al., 2009).
EXPERIMENTAL PROCEDURES
Study Populations
The DGI GWAS comprises geographically matched controls and discordant
sib-ships selected from Finland and Sweden (Saxena et al., 2007). For replica-
tion, the Botnia PPP, the HBCS, and the METSIM studies were used. For
prospective analysis the MPP was employed. Human pancreatic islets were
from deceased donors (24 female, 26 male), body mass index (BMI) 17.6–
36.6 kg/m2, aged 26–75 years. The twins were identified through The Danish
Twin Register. All participants gave informed consent for the studies and the
local ethics committees approved the protocols. The studies are described
in more detail in Supplemental Experimental Procedures.
Animals
Wild-type (Tfb1m+/+) and heterozygous (Tfb1m +/) male mice, 2–3 months of
age (Metodiev et al., 2009), were housed at 22Cwith a daylight period of 12 hr
and fed diet and water ad libitum. All experiments were approved by the local
Animal Ethics Committee.
Gene Expression
Total RNA was extracted from human muscle biopsies, islets, and clonal
b cells. TFB1M mRNA levels were quantified by TaqMan Real-Time PCR as
described in Supplemental Experimental Procedures.
RNA Interference
RNA interference in clonal INS-1 832/13 b cells is described in detail in Supple-
mental Experimental Procedures.CIntraperitoneal Glucose Tolerance Test
Intraperitoneal glucose tolerance tests were performed in fasted mice as
described (Fex et al., 2007).
Insulin Secretion and Content
Cells transfected with siRNA for Tfb1m or islets from Tfb1m +/+ and Tfb1m+/
mice were kept at 37C for 1 hr in 2.8 or 16.7 mM glucose or in 2.8 mM glucose
and 10 mM a-KIC. The buffer was removed and secreted insulin was deter-
mined. For insulin content, scraped cells were centrifuged and the supernatant
diluted 10 times in acidified ethanol prior to measurement; for details, see
Supplemental Experimental Procedures.
ATP and Citrate Synthase Activity Measurements
Cellular ATP content was measured with a luminescence assay. The rate of
mitochondrial ATP production in digitonin-permeabilized mouse islets and
clonal INS-1 832/13 cells was measured as previously described (Malmgren
et al., 2009). A Citrate Synthase Assay Kit (Sigma, St. Louis, MO) was used
according to instructions by the manufacturer. Enzymatic ATP hydrolysis
was assessed by a high-sensitivity ATPase assay kit (Innova Biosciences,
Babraham, Cambridge, UK) according to the instructions provided by the
manufacturer.
Oxygen Consumption Rate
To determine cellular OCR in INS-1 832/13 b cells, we used the Seahorse
XF24 Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, MA), which
measures OCR, as described (Malmgren et al., 2009). For details, see Supple-
mental Experimental Procedures.
ETS Complex Assays
Fifty micrograms of protein from mitochondria-enriched fraction pellets were
used to assay the activities of the mitochondrial ETS complexes I, III, and IV.
For details, see Supplemental Experimental Procedures.
Quantification of Mitochondrial DNA Content
Mitochondrial DNA content was assessed using a modification of the quanti-
tative real-time PCR-based method described previously (Reiling et al., 2010).
For details, see Supplemental Experimental Procedures.
Statistical Analysis
The statistical analyses are described in detail in Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four tables, three figures, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.cmet.2010.12.007.
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